OTCMKTS:BPMUF Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis $84.00 0.00 (0.00%) As of 11/17/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and TrendsShort Interest About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Basilea Pharmaceutica alerts:Sign Up Key Stats Today's Range$84.00▼$84.0050-Day Range$76.25▼$84.0052-Week Range$59.29▼$84.00VolumeN/AAverage Volume1 shsMarket Capitalization$1.11 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000 and headquartered in Basel. It focuses on developing and commercializing medicines for serious bacterial and fungal infections. The company’s products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic used for certain serious bacterial infections. Basilea makes its medicines available in multiple countries through a combination of its own commercial activities and partnerships. Availability and marketing arrangements vary by territory.AI Generated. May Contain Errors. Read More Basilea Pharmaceutica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreBPMUF MarketRank™: 1.30976846143 of 5 starsBasilea Pharmaceutica scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingBasilea Pharmaceutica has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBasilea Pharmaceutica has only been the subject of 1 research reports in the past 90 days.Read more about Basilea Pharmaceutica's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-10.48% Earnings GrowthEarnings for Basilea Pharmaceutica are expected to decrease by -10.48% in the coming year, from $8.49 to $7.60 per share.Price to Book Value per Share RatioBasilea Pharmaceutica has a P/B Ratio of 7.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Basilea Pharmaceutica has been sold short.Short Interest Ratio / Days to CoverBasilea Pharmaceutica has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Basilea Pharmaceutica has recently decreased by 64.58%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBasilea Pharmaceutica does not currently pay a dividend.Dividend GrowthBasilea Pharmaceutica does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.64 News SentimentBasilea Pharmaceutica has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Basilea Pharmaceutica this week, compared to 0 articles on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Basilea Pharmaceutica insiders have not sold or bought any company stock.Percentage Held by InstitutionsBasilea Pharmaceutica has minimal institutional ownership at this time.Read more about Basilea Pharmaceutica's insider trading history. Receive BPMUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPMUF Stock News HeadlinesBrokers Offer Predictions for OTCMKTS:BPMUF FY2026 Earnings2 hours ago | americanbankingnews.comHC Wainwright Estimates OTCMKTS:BPMUF FY2027 EarningsNovember 16 at 2:13 AM | americanbankingnews.comUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it. | Profits Run (Ad)Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Sees Large Decline in Short InterestNovember 14, 2026 | americanbankingnews.comBasilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactamMay 28, 2026 | globenewswire.comBasilea shareholders approve all proposals of the board of directors at the 2026 annual general meetingApril 15, 2026 | globenewswire.comBasilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420April 9, 2026 | globenewswire.comBasilea announces start of first‑in‑human study of novel antibiotic BAL2420March 23, 2026 | globenewswire.comSee More Headlines BPMUF Stock Analysis - Frequently Asked Questions How have BPMUF shares performed this year? Basilea Pharmaceutica's stock was trading at $63.25 at the beginning of the year. Since then, BPMUF shares have increased by 32.8% and is now trading at $84.00. Does Basilea Pharmaceutica have any subsidiaries? Basilea Pharmaceutica subsidiaries include Conec UK Limited. How do I buy shares of Basilea Pharmaceutica? Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:BPMUF CIKN/A Webwww.basilea.com Phone(161) 606-1111Fax41-61-606-1112Employees189Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.44 Current Ratio6.60 Quick Ratio5.97 Sales & Book Value Annual Sales$280.43 million Price / Sales3.94 Cash Flow$3.85 per share Price / Cash Flow21.82 Book Value$11.73 per share Price / Book7.16Miscellaneous Outstanding Shares13,170,000Free FloatN/AMarket Cap$1.11 billion OptionableNot Optionable Beta0.22 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (OTCMKTS:BPMUF) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Basilea Pharmaceutica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.